These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20109144)

  • 41. A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions.
    Feng M; Sparkman NL; Sui N; Li M
    J Psychopharmacol; 2017 Apr; 31(4):474-486. PubMed ID: 28347260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
    Shannon HE; Hart JC; Bymaster FP; Calligaro DO; DeLapp NW; Mitch CH; Ward JS; Fink-Jensen A; Sauerberg P; Jeppesen L; Sheardown MJ; Swedberg MD
    J Pharmacol Exp Ther; 1999 Aug; 290(2):901-7. PubMed ID: 10411607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
    Amato D; Vernon AC; Papaleo F
    Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine.
    Björkholm C; Jardemark K; Marcus MM; Malmerfelt A; Nyberg S; Schilström B; Svensson TH
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):709-20. PubMed ID: 22732518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.
    Franke RT; Tarland E; Fink H; Pertz HH; Brosda J
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3041-50. PubMed ID: 27317020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antipsychotic profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562) in rats.
    Takamori K; Funakoshi T; Hirota S; Chaki S; Kameo K
    Life Sci; 2002 Jul; 71(8):947-52. PubMed ID: 12084391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of postsynaptic D2 dopamine receptors in the rat dorsolateral striatum prevents the amnestic effect of systemically administered neuroleptics.
    Boschen SL; Andreatini R; da Cunha C
    Behav Brain Res; 2015 Mar; 281():283-9. PubMed ID: 25546724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
    Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
    Nadal R
    CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.